A prospective study of autoantibodies to Ezrin and pancreatic cancer risk

Cancer Causes Control. 2016 Jun;27(6):831-5. doi: 10.1007/s10552-016-0757-y. Epub 2016 May 4.


Purpose: No biomarker is available for pancreatic cancer early detection, but a small prospective European study involving 16 cases and 32 controls raised the possibility that anti-Ezrin autoantibodies may be associated with risk of pancreatic cancer. We aimed to validate this finding in a case-control study nested within a prospective study in the USA.

Methods: Levels of anti-Ezrin autoantibodies were examined using ELISA in pre-diagnostic plasma samples of 73 cases and 145 matched controls. Paired t test and paired signed rank tests were used to determine the difference between two groups, and conditional logistic regression was used to evaluate the association between anti-Ezrin autoantibody levels and risk of developing pancreatic cancer.

Results: No association was found between levels of anti-Ezrin plasma autoantibodies and subsequent risk of developing pancreatic cancer.

Conclusion: Anti-Ezrin autoantibodies did not appear to be useful as a plasma biomarker for early detection of pancreatic cancer.

Keywords: Autoantibodies; Ezrin; Pancreatic cancer risk; Prospective study.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Autoantibodies / immunology*
  • Case-Control Studies
  • Cytoskeletal Proteins / immunology*
  • Early Detection of Cancer
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / epidemiology
  • Pancreatic Neoplasms / immunology*
  • Prospective Studies
  • Risk
  • United States / epidemiology


  • Autoantibodies
  • Cytoskeletal Proteins
  • ezrin